CDK6 Overexpression serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Overexpression as an inclusion criterion, 1 is phase 2/phase 3 (1 open).
Trials with CDK6 Overexpression in the inclusion eligibility criteria most commonly target squamous cell lung carcinoma .
Medi-4736, durvalumab, ipilimumab, nivolumab, and palbociclib are the most frequent therapies in trials with CDK6 Overexpression as an inclusion criteria .
Significance of CDK6 Overexpression in Diseases
Squamous Cell Lung Carcinoma +
CDK6 is mutated in 0.86% of squamous cell lung carcinoma patients .
CDK6 Overexpression is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Overexpression and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) .
Medi-4736, durvalumab, and ipilimumab are the most frequent therapies in trials for squamous cell lung carcinoma that contain CDK6 Overexpression .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.